Read more on the ACHIEVE-3 results here: To view or add a comment, sign in Novo Nordisks next-generation obesity drug CagriSema failed to outperform Eli Lillys Zepbound in a recent head-to-head Phase 3 trial, missing its primary goal and underscoring the intense competition and high stakes in the obesity drug market
Plus aiding weight loss, Semaglutide has been found to improve insulin sensitivity, reduce blood sugar levels, and lead to a decreased risk of heart disease in people with diabetes
Canadian journal of diabetes
The frequencies of event adjudication committee-confirmed events, including acute kidney injury, cardiovascular events and malignant neoplasms, were low and similar across all treatment arms in the overall population (ESM Table 4)
Regular skin checks and prompt attention to any suspicious growths are essential steps in managing this type of skin cancer